Stock Analysis on Net

Cytokinetics Inc. (NASDAQ:CYTK)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Economic Value Added (EVA)

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Economic Profit

Cytokinetics Inc., economic profit calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2022 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


Net Operating Profit After Taxes (NOPAT)
The NOPAT exhibits a persistent negative trend throughout the observed periods, indicating ongoing operational losses. The magnitude of these losses fluctuates significantly, with the most substantial loss recorded in the latest year. Notably, there was a notable improvement in 2020 compared to previous years, as the loss decreased substantially, but this was followed by a sharp deterioration in subsequent years, reaching the highest negative value by the end of 2022.
Cost of Capital
The cost of capital shows relatively minor fluctuations over the years, maintaining a range between approximately 12.4% and 13.3%. This stability suggests that the external financing environment and the risk profile perceived by investors have not experienced significant changes during the period. The slight decrease toward the end of the timeline indicates a modest reduction in the cost of capital by 2022.
Invested Capital
Invested capital data reflects considerable volatility, with negative values in most years except for 2021. The negative invested capital figures may imply accounting anomalies, significant liabilities, or other adjustments affecting the capital base. The positive value observed in 2021 contrasts with the general trend and might signal a one-time event or reclassification. However, by 2022, the invested capital returned to negative territory, deepening the negative value, which could suggest increased leverage or capital depletion.
Economic Profit
Economic profit remains consistently negative across all years, mirroring the pattern of negative NOPAT and the implications of cost of capital consumption exceeding returns. The largest negative economic profit occurs in 2022, indicating that the company has been generating returns well below its cost of capital and thereby destroying shareholder value. There was slight improvement in 2020, similar to the trend observed in NOPAT, but this was temporary as losses intensified significantly afterwards.

Net Operating Profit after Taxes (NOPAT)

Cytokinetics Inc., NOPAT calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net loss
Deferred income tax expense (benefit)1
Increase (decrease) in deferred revenue2
Increase (decrease) in equity equivalents3
Interest expense
Interest expense, operating lease liability4
Adjusted interest expense
Tax benefit of interest expense5
Adjusted interest expense, after taxes6
Interest income
Investment income, before taxes
Tax expense (benefit) of investment income7
Investment income, after taxes8
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in deferred revenue.

3 Addition of increase (decrease) in equity equivalents to net loss.

4 2022 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

5 2022 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =

6 Addition of after taxes interest expense to net loss.

7 2022 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

8 Elimination of after taxes investment income.


Net Loss Trend
The net loss demonstrates a consistent and significant increase over the five-year period. Beginning at approximately -106.3 million US dollars at the end of 2018, the net loss gradually worsened to -121.7 million in 2019 and further to -127.3 million in 2020. A sharper escalation is observed in 2021, with the net loss reaching approximately -215.3 million US dollars, followed by a substantial further decline to -389.0 million US dollars in 2022. This indicates increasing expenses, reduced revenues, or other factors contributing to growing financial challenges over time.
Net Operating Profit After Taxes (NOPAT) Trend
NOPAT follows a somewhat different trajectory from net loss but remains negative throughout the observed period. It starts at around -105.9 million US dollars in 2018 and deteriorates slightly to -119.5 million in 2019. In 2020, there is a notable improvement, with NOPAT improving substantially to approximately -31.6 million US dollars, indicating either a reduction in operating losses or improved operational efficiency during that year. However, this improvement is not sustained, as NOPAT declines sharply in 2021 to around -193.1 million, and further worsens to an estimated -460.0 million US dollars by the end of 2022. This sharp downturn in recent years suggests significant operational challenges impacting profitability after taxes.
Overall Financial Performance Insights
The increasing net losses alongside the fluctuating but largely negative NOPAT values suggest persistent financial difficulties with a notable deterioration in both net loss and operating profitability in the last two years of the data. The brief improvement in NOPAT in 2020 could reflect transient operational efficiencies or cost management, which were not maintained amid subsequent increases in losses. This pattern may warrant a deeper investigation into the underlying causes such as increased expenses, investments, or operational disruptions in the 2021 and 2022 periods.

Cash Operating Taxes

Cytokinetics Inc., cash operating taxes calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Income tax provision
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


The data presents a clear upward trend in cash operating taxes for the company over the observed period from December 31, 2018, to December 31, 2022. Starting at 102 thousand US dollars in 2018, the cash operating taxes increased significantly each year, peaking at 5,911 thousand US dollars by the end of 2021. However, in 2022, there was a noticeable decline to 4,236 thousand US dollars, indicating a reduction of approximately 28% from the previous year.

The absence of values for the income tax provision across all periods indicates either that such data was not reported or that there were no income tax provisions recognized during these years.

Overall, the cash operating taxes show a consistent upward trajectory with the exception of the last year, where a decline suggests possible changes in tax policy, operational conditions, or other factors impacting the tax liability related to cash operations. The lack of income tax provision data limits the ability to analyze comprehensive tax expense trends.


Invested Capital

Cytokinetics Inc., invested capital calculation (financing approach)

US$ in thousands

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Current portion of term loan
Short-term finance lease liabilities
Term loan, net, excluding current portion
Convertible notes, net
Long-term finance lease liabilities
Operating lease liability1
Total reported debt & leases
Stockholders’ equity (deficit)
Net deferred tax (assets) liabilities2
Deferred revenue3
Equity equivalents4
Accumulated other comprehensive (income) loss, net of tax5
Adjusted stockholders’ equity (deficit)
Construction in progress6
Available-for-sale investments7
Invested capital

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of deferred revenue.

4 Addition of equity equivalents to stockholders’ equity (deficit).

5 Removal of accumulated other comprehensive income.

6 Subtraction of construction in progress.

7 Subtraction of available-for-sale investments.


Total reported debt & leases
The total reported debt and leases show a consistent and significant upward trend over the five-year period. Beginning at $52.8 million in 2018, the figure rose sharply to $136.1 million in 2019 and remained relatively stable in 2020. From 2020 onwards, the debt level surged substantially, reaching $271.2 million in 2021 and further increasing to $751.3 million by the end of 2022. This dramatic rise in debt indicates a growing reliance on external financing or obligations over time.
Stockholders’ equity (deficit)
Stockholders’ equity exhibits considerable volatility throughout the period. Initially, it was positive at $25.9 million in 2018. However, it turned negative in 2019, reflecting a deficit of approximately $10.9 million. The position improved markedly in 2020 and 2021, reaching a peak value of $243.9 million in 2021, indicating a strong equity base during these years. Nevertheless, by the end of 2022, stockholders’ equity declined sharply into a deficit of $107.9 million, suggesting a deterioration in the company’s net asset position in the most recent year.
Invested capital
Invested capital remained negative for the majority of the analyzed period, starting at a deficit of $78.3 million in 2018 and worsening slightly to $106.9 million in 2019. There was a modest improvement in 2020, yet the figure remained negative. A notable positive shift occurred in 2021, with invested capital rising to a positive $91.7 million, implying effective investment and capital utilization during that year. This positive trend was reversed in 2022, with invested capital declining sharply back into negative territory at $117.4 million, reflecting a significant decrease in net capital invested in the company.

Cost of Capital

Cytokinetics Inc., cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2022-12-31).

1 US$ in thousands

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-12-31).

1 US$ in thousands

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2020-12-31).

1 US$ in thousands

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2019-12-31).

1 US$ in thousands

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2018-12-31).

1 US$ in thousands

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

Cytokinetics Inc., economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in thousands)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2022 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


The financial data presents several key insights into the economic performance and capital structure over a five-year period.

Economic Profit

The economic profit figures exhibit significant volatility and a predominantly negative trend throughout the period. Starting from a loss of approximately $95.5 million in 2018, the loss increased to about $105.4 million in 2019. There was a noticeable reduction in the economic loss in 2020 to approximately $20.6 million, indicating an improvement in profitability dynamics for that year. However, this was followed by a sharp deterioration in 2021, with the loss escalating dramatically to about $205.1 million, and a further substantial increase in 2022, reaching a negative $445.4 million. This escalating loss suggests worsening profitability or increasing costs/investment inefficiencies over the last two years.

Invested Capital

The invested capital figures reflect considerable fluctuations and inconsistencies in the capital base. The values were negative in 2018 and 2019, standing at roughly -$78.3 million and -$106.9 million, respectively, which may indicate net liabilities or accounting adjustments in capital employed. In 2020, the negative value reduced to about -$88.0 million, implying some form of capital restructuring or reduction in net liabilities. A significant change is observed in 2021 when the invested capital sharply turned positive to approximately $91.7 million, reflecting a possible capital infusion or asset revaluation. However, this reversal was short-lived, as the invested capital swung back to negative territory in 2022 at around -$117.4 million, marking the lowest capital base in absolute terms during the period analyzed.

Economic Spread Ratio

Data for the economic spread ratio is largely missing except for 2021, where a substantial negative value of -223.63% is recorded. This ratio measure typically indicates the return generated on invested capital relative to its cost, and the substantial negative figure aligns with the observed negative economic profit and volatile invested capital in 2021, pointing toward inefficient capital utilization during that year.

In summary, the data reveals a challenging financial environment with persistent and deepening economic losses, combined with unstable invested capital figures. The occasional improvements, such as the temporary reduction in losses in 2020 and the positive shift in invested capital in 2021, were not sustained, indicating ongoing operational or strategic difficulties in achieving economic profitability and stable capital management.


Economic Profit Margin

Cytokinetics Inc., economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in thousands)
Economic profit1
 
Revenues
Add: Increase (decrease) in deferred revenue
Adjusted revenues
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Economic profit. See details »

2 2022 Calculation
Economic profit margin = 100 × Economic profit ÷ Adjusted revenues
= 100 × ÷ =

3 Click competitor name to see calculations.


Economic Profit
The economic profit experienced significant fluctuations over the analyzed periods. Initially, there was a negative economic profit of approximately -95.5 million USD in 2018, which worsened to about -105.4 million USD in 2019. In 2020, the economic loss decreased substantially to around -20.6 million USD, indicating some improvement. However, this trend reversed sharply in 2021, with economic profit deteriorating again to approximately -205.1 million USD and declining even further to about -445.4 million USD in 2022, reflecting a substantial increase in economic losses.
Adjusted Revenues
Adjusted revenues showed variability with a notable peak and subsequent decline. From 2018 to 2019, revenues slightly decreased from roughly 31.5 million USD to 26.9 million USD. In 2020, revenues surged markedly to around 142.8 million USD, representing a significant growth phase. However, this increase was not sustained, as revenues dropped to about 70.4 million USD in 2021 and further declined sharply to approximately 7.6 million USD in 2022, indicating a steep reduction in revenue-generating capacity.
Economic Profit Margin
The economic profit margin remained negative throughout the period, underscoring persistent unprofitability relative to revenues. It began at -303.14% in 2018 and deteriorated to -392.28% in 2019, indicating increasing losses relative to revenue. In 2020, the margin improved substantially to -14.46%, coinciding with the revenue spike and reduced economic loss. However, this improvement was short-lived as the margin worsened again to -291.25% in 2021 and declined dramatically to -5869.4% in 2022, highlighting a disproportionate increase in economic losses relative to revenues in that year.
Overall Trends and Insights
The company displayed volatile financial performance over the five-year span. The brief improvement in 2020, characterized by increased revenues and reduced economic losses, was followed by a sharp decline in both revenue and profitability. The extreme deterioration in economic profit and margin in 2022 suggests challenges in cost management, market conditions, or operational effectiveness. The persistent negative economic profit margin indicates the company's operations were significantly unprofitable in relation to its revenues throughout the period. These patterns suggest a need for strategic reassessment to address the underlying factors contributing to the substantial economic losses.